ArticleThe Journal of experimental medicine2010
Erythropoietin protects against diabetes through direct effects on pancreatic beta cells.
Article in The Journal of experimental medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 127 citations in OpenAlex.
- Erythropoietin promotes cell proliferation in Neuro-2A mouse neuroblastoma cells.Biochemistry and biophysics reports · 2025Article
- Malignant JAK-signaling: at the interface of inflammation and malignant transformation.Leukemia · 2025Review
- A direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice.Science advances · 2025Article
- Article
- Hypophosphorylated pRb knock-in mice exhibit hallmarks of aging and vitamin C-preventable diabetes.The EMBO journal · 2022Article
- Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.Therapeutic advances in endocrinology and metabolism · 2022Review
- Erythropoietin exposure of isolated pancreatic islets accelerates their revascularization after transplantation.Acta diabetologica · 2021Article
- STAT5 as a Key Protein of Erythropoietin Signalization.International journal of molecular sciences · 2021Review
- Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.Molecular cancer research : MCR · 2021Article
- The influence of erythropoietin on apoptosis and fibrosis in the early phase of chronic pancreatitis in rats.Archives of medical science : AMS · 2021Article
- Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements inFrontiers in immunology · 2021Article
- Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone.Frontiers in immunology · 2021Review
- Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan.Therapeutic advances in chronic disease · 2021Article
- Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain, and bone.Experimental hematology · 2020Review
- Erythropoietin accelerates the revascularization of transplanted pancreatic islets.British journal of pharmacology · 2020Article
- Regulation of muscle and metabolic physiology by hypothalamic erythropoietin independently of its peripheral action.Molecular metabolism · 2020Article
- Effects of Erythropoietin in White Adipose Tissue and Bone Microenvironment.Frontiers in cell and developmental biology · 2020Review
- Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Review
- Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes.Scientific reports · 2019Article
- Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research.Animal cells and systems · 2019Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
Abstract
A common feature among all forms of diabetes mellitus is a functional β-cell mass insufficient to maintain euglycemia; therefore, the promotion of β-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic β cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using β-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on β cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in β cells may be a novel therapeutic strategy for diabetes prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.